Abstract
The ESGO/ESTRO/ESP guidelines for endometrial cancer published in November 2020 in the International Journal of Gynaecological Cancer gave us a trailblazing guide to steer our wheels in the precisely carved direction for the treatment of endometrial cancer, the commander being the molecular markers(TP53, MSH6, PMS2 and POLE mutation). Since the complete molecular profiling is not feasible in a low middle income country like India we started getting the tissues of endometrial carcinoma tested for TP53 mutation because its mutation can label even a low risk disease to high risk disease, worsening the treatment outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
